Antimicrobial resistance of Helicobacter pylori. Clinical and molecular aspects;Resistencia antimicrobiana en Helicobacter pylori: Aspectos clínicos y moleculares

Revista Medica de Chile

Volumn 131, Issue 11, 2003, Pages 1313-1320

  Vallejos M, Cristián ^a   Cerda A, Oscar ^a   Valenzuela V, Manuel ^a   Toledo A, Héctor ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Antibiotics, combined; Drug therapy, combinations; Helicobacter pylori; Microbial sensitivity tests

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; METRONIDAZOLE; TETRACYCLINE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; CHILE; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOST; MEDICAL INFORMATION; MOLECULAR BIOLOGY; NONHUMAN; REVIEW; STOMACH DISEASE; STOMACH MUCOSA; DRUG EFFECT; HUMAN;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; TETRACYCLINES;

EID: 1842560268     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. WARREN JR, MARSHALL B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet i, 1983; 1273-5.
2. GRAHAM DY. Helicobacter pylori is not and never was " protective" against anything, including GERD. Dig Dis Sci 2003; 48: 629-30.
3. GRAHAM DY. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med 1993; 328: 349-50.
4. HENTSCHEL E, BRANDSTATTER G, DRAGOSICS B, HIRSCHL AM, NEMEC H, SCHUTZE K ET AL. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-12.
5. KUIPERS EJ, THIJS JC, FESTEN HPM. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9: S59-S69.
6. FORMAN D. The prevalence of Helicobacter pylori infection in gastric cancer. Aliment Pharmacol Ther 1995; 9: S71-S76.
7. COVER TL, BLASER MJ. Helicobacter pylori infection, a paradigm for chronic mucosal inflammation pathogenesis and implication for eradication and prevention. Adv Intern Med 1996; 41: 85-117.
8. DUNN BE, COHEN H, BLASER MJ. Helicobacter pylori. Clin Microbiol Rev 1997; 10: 720-41.
9. VALENZUELA J. Helicobacter pylori: la revolución bacteriológica. Rev Méd Chile 1999; 127: 891-3.
10. TAYLOR DN, PARSONNET J. Epidemiology and natural history of H pylori infections of the gastrointestinal tract. In: Blaser MJ, Smith PF, Ravdin J, Greenberg H. and Guerrant RL (eds). New York: Raven Press, 1995; 551-564.
11. FIGUEROA G, ACUÑA R, TRONCOSO M, PORTELL DP, TOLEDO MS, VALENZUELA J. Helicobacter pylori Infection in Chile. Clin Infec Diseas 1997; 25: 983-9.
12. NIH CONSENSUS CONFERENCE. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Pannel on Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9.
13. WU H, SHI XD, WANG HT, LIU JX. Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrob Chemother 2000; 46: 121-3.
14. PENSTON JG, MCCOLL KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-43
15. KIM JJ, KIM JG, KWON DH. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolated in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 2003; 8: 202-6.
16. CHIBA N, RAO BV, RADEMAKER JW, HUNT RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-26.
17. GRAHAM DY, LEW GM, KLEIN PD, ALPERT L-C, GENTA RM. Factors affecting the eradication of Helicobacter pylori infection with triple therapy. Gastroenterology 1992; 192: 163-7.
18. GRAHAM DY. Antibiotic resistance in Helicobacter pylori: implication for therapy. Gastroenterology 1998; 115: 1272-7.
19. PANTOFLICKOVA D, BLUM AL. Antagonist. Should we eradicate Helicobacter pylori in non-ulcer dyspepsia? Gut 2001; 48: 758-61.
20. MCCOLL KEL. Protagonista. Should we eradicate Helicobacter pylori in non-ulcer dyspepsia? Gut 2001; 48: 758-61.
21. ADAMSSON I, NORD CE, LUNQUIST P, LUNDQUIST P, SJOSTEDT S, EDLUND C. Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori infected patients. J Antimicrob Chemother 1999; 44: 629-40.
22. VAN DER WOUDEN EJ, THIJS JC, VAN ZWEL WJ, SLUITER WJ, KLEIBEUKER JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999; 94: 1751-9.
23. MIYAJI H, AZUMA T, ITO S, SUTO H, ITO Y, YAMAZAKI Y ET AL. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromicyn and amoxycillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther 1997; 11: 1131-6.
24. MUKHOPADHYAY AK, KERSULYTE D, JEONG JY, DATTA S, ITO Y, CHOWDHURY A ET AL. Distintiveness of genotype of Helicobacter pylori in Calcutta, India. J Bacteriol 2000; 182: 3219-27.
25. GLUPCZYNSKI Y. Antimicrobial resistance in Helicobacter pylori: a global overview. Acta Gastroenterol. Belgium 1998; 61: 357-66.
26. MEGRAUND F, LEHN N, LIND T, BAYERDORFFER E, O'MORAIN C, SPILLER R ET AL. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: The MACH 2 study. Antimicrob. Agents Chemother 1999; 43: 2747-52.
27. GONZÁLEZ C, GARCÍA A, DAROCH F, KAWAGUCHI F, SOLAR H, RIVERA N ET AL. Susceptibilidad in vitro de cepas de Helicobacter pylori: aislamiento de cepas resistentes a claritromicina. Rev Méd Chile 2001; 129: 643-6.
28. DORE MP, OSATO MS, REALDI G, MURA I, GRAHAM DY, SEPÚLVEDA AR. Amoxycillin tolerance in Helicobacter pylori. J Antimicrob Chemother 1999; 43: 47-54.
29. HEEP M, KIST M, STROBEL S, BECK D, LEHN N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000; 19: 538-41.
30. VANDOORN L-J, DEBETS-OSSENKOPP YJ, MARAIS A, SANNA R, MEGRAUD F, KUSTERS JG ET AL. Rapid detection, by PCR and Reverse Hybridization, of Mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance. Antimicrob Agents Chemother 1999; 43: 1779-82.
31. VERSALOVIC J, SHORTRIDGE D, KIBLER K, GRIFFY MV, BEYER J, FLAMM RK ET AL. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40: 477-80.
32. OCCHIALINI A, URDACI M, DOUCET-POPULAIRE F, BEBEAR CM, LAMOULIATTE H, MEGRAUD F. Macrolide resistance in Helicobacter pylori: rapid detection of point mutation and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997; 41: 2724-8.
33. VERSALOVIC J, OSATO MS, SPAKOVSKY K, DORE MP, REDDY R, STONE GG ET AL. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 1997; 40: 283-6.
34. STONE GG, SHORTRIGE D, VERSALOVIC J, BEYER J, FLAMM RK, GRAHAM DY ET AL. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rDNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother 1997; 41: 712-4.
35. EDWARDS DI. Nitroimidazole drugs-action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 1993; 31: 9-20.
36. SISSON G, JEONG J-Y, GOODWIN A, BRYDEN L, ROSSLER N, LIM-MORRISON S ET AL. Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori rdxA+ (nitroreductase) gene. J Bacteriol 2001; 182: 5091-6.
37. JEONG J-Y, MUKHOPADHYAY AK, AKADA JK, DAILIDIENE D, HOFFMAN PS, BERG DE. Roles of FrxA and RdxA nitroreductases of Helicobacter pylori in susceptibility and resistance to metronidazole. J Bacteriol 2001; 183: 5155-62.
38. JEONG J-Y, MUKHOPADHYAY AK, DAILIDIENE D, WANG Y, VELAPATINO B, GILMAN RH ET AL. Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high level metronidazole resistance in Helicobacter pylori. J Bacteriol 2000; 182: 5082-90.
39. TOMB JF, WHITE O, KERLAVAGE AR, CLAYTON RA, SUTTON GG, FLEISCHMANN RD ET AL. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997; 388: 539-47.
40. GOODWIN A, KERSULYTE D, SISSON G, VELDHUYZEN VAN ZANTEN SJ, BERG DE, HOFFMAN PS ET AL. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol 1998; 28: 383-93.
41. HAN SR, BHAKDI S, MAEURER MJ, SCHNEIDER T, GEHRING S. Stable and unstable amoxycillin resistance in Helicobacter pylori: should antibiotic resistance testing be performed prior to eradication therapy? J Clin Microbiol 1999; 37: 2740-1.
42. VAN ZWET AA, VANDENBROUCKE-GRAULS CMJE, THIJS JC, VAN DER WOUDEN EJ, GERRITS MM, KUSTERS JG ET AL. Stable amoxycillin in Helicobacter pylori. Lancet 1998; 352: 1595.
43. SMITH SI, OYEDEJI KS, ARIGBABU AO, ATIMOMO C, COKER AO. High amoxycillin resistance in Helicobacter pylori isoleted from gastritis and peptic ulcer patients in western Nigeria. J Gastroenterology 2001; 36: 67-8.
44. OKAMOTO T, YOSHIYAMA H, NAKAZAWA T, PARK ID, CHANG MW, YANAI H ET AL. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother 2002; 50: 849-56.
45. TRIEBER CA, TAYLOR DE. Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to Tetracycline. J Bacteriol 2002; 184: 2131-40.
46. MILADO PD, KORMAN MG, TURNIDGE JD, LAMBERT JR. Helicobacter pylori resistance to tetracycline. Lancet 1996; 347: 1194-5.
47. KWON DH, KIM JJ, LEE M, YAMAOKA Y, KATO M, OSATO MS ET AL. Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44: 3203-5.
48. DAILIDIENE D, BERTOLI MT, MICIULEVICIENE J, MUKHOPADHYAY AK, DAILIDE G, PASCASIO MA ET AL. Emergence of Tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrob Agents Chemother 2002; 46: 3940-6.